#USA #New York #Securities Fraud #Tenax Therapeutics #TNX-103

Tenax Therapeutics Faces Investigation Following Massive Share Price Drop

In a shocking turn of events, Tenax Therapeutics (NASDAQ: TENX) has reported a catastrophic loss in share value, ranging from 84% to 85%. This drastic decline ignited following the announcement that its Phase 3 LEVEL trial of TNX-103 failed to meet both its primary and key secondary endpoints. This outcome has raised serious questions not only about the drug's efficacy but also about the company's transparency leading up to this point.

The Phase 3 LEVEL Trial: What Went Wrong?

The LEVEL trial was essential for validating TNX-103 as a treatment option for patients with Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The company announced that TNX-103 achieved only a placebo-adjusted improvement of 3.5 meters in the six-minute walk distance—an outcome deemed statistically insignificant. Moreover, the Kansas City Cardiomyopathy Questionnaire symptom score revealed virtually no difference from placebo, heightening concerns amongst stakeholders.

This trial was prescriptive for Tenax Therapeutics, as the company is still pre-revenue and relying heavily on the success of TNX-103 to establish a foothold in a competitive market. The potential market value of TNX-103 was previously gauged with high expectations, making this outcome particularly devastating.

Investigating Potential Securities Law Violations

In light of the trial's disappointing results, Levi & Korsinsky is leading an investigation into possible securities law violations on behalf of investors who experienced losses. Investors who purchased TENX securities and suffered equitable losses are being encouraged to partake in this inquiry. The firm specializes in handling complex securities litigation, and its history includes recovering hundreds of millions of dollars for investors.

As a necessary step, affected investors are urged to compile their brokerage records, demonstrating purchase dates, quantities, and costs associated with their investments. This documentation is crucial as it forms the basis for evaluating potential recovery from Tenax’s disappointing trial outcomes.

What Should Investors Do Now?

For those who have lost money as a result of the TNX-103 trial results, there are immediate actions to consider:

• - Gather Records: Compile relevant documentation, including brokerage statements and trade confirmations.
• - Contact Legal Experts: It's vital to consult with professionals in securities law to better understand your rights and potential path for recovery.
• - Stay Updated: Monitoring updates from Tenax and the ongoing investigation can provide insights into your eligibility for involvement in any legal recourse.

The call to action extends to all investors, regardless of the extent of their losses. There is no minimum loss amount required for participation in the investigation, emphasizing the commitment to supporting all stakeholders.

Conclusion

The situation surrounding Tenax Therapeutics serves as a stark reminder of the volatile nature of biotech stocks, particularly when clinical trials do not yield favorable outcomes. Investors must exercise caution and stay informed as developments unfold. The Tenax case will likely prompt deeper scrutiny into the regulatory obligations of clinical-stage companies and reinforce the need for stringent risk disclosures to investors.

For interested investors, follow up with Levi & Korsinsky for a risk-free assessment of your case, as they continue to advocate for shareholders and support their search for justice in the wake of financial losses stemming from this unmet trial challenge.